{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:55Z","timestamp":1790913715805,"version":"4.1.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since the introduction of imatinib, the management of chronic myeloid leukemia (CML) has changed considerably. Tyrosine kinase inhibitors (TKIs) are the mainstay of CML treatment; however, the high financial burden of TKIs can be problematic for both the patients and health care systems. After the emergence of generics, reimbursement policies of many countries have changed, and generics offered an alternative treatment option for CML patients. There are many papers published on the use of generics in CML patients with conflicting results regarding both efficacy and safety. In this paper, we systematically reviewed the current literature on generic imatinib use in CML, and 36 papers were evaluated. Both in vitro and in vivo studies of generic imatinib showed comparable results with branded imatinib in terms of bioequivalence and bioavailability. In most studies, generics were comparable with the original molecule in terms of efficacy and safety, both in newly diagnosed patients and after switching from Gleevec. Some generic studies showed contradictory findings regarding efficacy and toxicity, and these differences can be attributed to some factors including the use of different generics in different countries. Both in hypothetical models and in real life, introduction of generic imatinib caused significant reduction in health care costs. In conclusion, generics are not inferior to original imatinib in terms of efficacy with an acceptable toxicity profile. Notwithstanding the generally favorable efficacy and safety of generics worldwide to date, we most probably still need more time to draw firmer conclusions on the longer-term outcomes of generics.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004194","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:54:51Z","timestamp":1630670091000},"page":"3344-3353","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs"],"prefix":"10.1182","volume":"5","author":[{"given":"Abd\u00fclkadir","family":"Er\u00e7al\u0131\u015fkan","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Seyhan Erdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"10","key":"2021090315385646100_B1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"2021090315385646100_B2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"issue":"10","key":"2021090315385646100_B3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/17474086.2020.1813564","article-title":"Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?","volume":"13","author":"Yilmaz","year":"2020","journal-title":"Expert Rev Hematol."},{"issue":"6","key":"2021090315385646100_B4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/17474086.2014.966679","article-title":"Generics in chronic myeloid leukemia: current arguments for and against and the established evidence","volume":"7","author":"Soysal","year":"2014","journal-title":"Expert Rev Hematol."},{"issue":"4","key":"2021090315385646100_B5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00432-018-2594-8","article-title":"Patients\u2019 and hematologists\u2019 concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia","volume":"144","author":"Jiang","year":"2018","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"2021090315385646100_B6","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1186\/1752-1947-3-7112","article-title":"Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report","volume":"3","author":"Goubran","year":"2009","journal-title":"J Med Case Reports."},{"issue":"1","key":"2021090315385646100_B7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12185-009-0431-1","article-title":"Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase","volume":"91","author":"Mattar","year":"2010","journal-title":"Int J Hematol."},{"issue":"12","key":"2021090315385646100_B8","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2014.893302","article-title":"Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety","volume":"55","author":"Saavedra","year":"2014","journal-title":"Leuk Lymphoma."},{"issue":"12","key":"2021090315385646100_B9","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3109\/10428194.2014.904508","article-title":"Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back","volume":"55","author":"Alwan","year":"2014","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2021090315385646100_B10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jps.22772","article-title":"Conformational polymorphism on imatinib mesylate: grinding effects","volume":"101","author":"Grillo","year":"2012","journal-title":"J Pharm Sci."},{"issue":"3","key":"2021090315385646100_B11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1248\/bpb.b14-00652","article-title":"Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec\u2122 tablet and its generic formulation, OHK9511","volume":"38","author":"Yokoo","year":"2015","journal-title":"Biol Pharm Bull."},{"issue":"8","key":"2021090315385646100_B12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clml.2016.04.003","article-title":"Comparison of branded and generic imatinib plasma concentrations in patients with chronic myelogenous leukemia: unicentric study","volume":"16","author":"Ostojic","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"2","key":"2021090315385646100_B13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/10428194.2018.1485907","article-title":"Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia","volume":"60","author":"Natarajan","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"11","key":"2021090315385646100_B14","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.3109\/10428194.2014.885515","article-title":"Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia","volume":"55","author":"Malhotra","year":"2014","journal-title":"Leuk Lymphoma."},{"issue":"8","key":"2021090315385646100_B15","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood."},{"issue":"8","key":"2021090315385646100_B16","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood."},{"issue":"3","key":"2021090315385646100_B17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4143\/crt.2015.436","article-title":"A multi-centric bioequivalence trial in Ph+ chronic myeloid leukemia patients to assess bioequivalence and safety evaluation of generic imatinib mesylate 400 mg tablets","volume":"48","author":"Arora","year":"2016","journal-title":"Cancer Res Treat."},{"issue":"5","key":"2021090315385646100_B18","first-page":"843","article-title":"Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers","volume":"71","author":"Ostrowicz","year":"2014","journal-title":"Acta Pol Pharm."},{"issue":"10","key":"2021090315385646100_B19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.clinthera.2009.10.009","article-title":"Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers","volume":"31","author":"Parrillo-Campiglia","year":"2009","journal-title":"Clin Ther."},{"issue":"12","key":"2021090315385646100_B20","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3109\/10428194.2014.905774","article-title":"The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia","volume":"55","author":"Eskazan","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"2021090315385646100_B21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2018.09.018","article-title":"Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy","volume":"74","author":"Bonifacio","year":"2018","journal-title":"Leuk Res."},{"issue":"2","key":"2021090315385646100_B22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.31768\/2312-8852.2017.39(2):151-154","article-title":"Generic imatinib in the treatment of chronic myeloid leukemia: two years\u2019 experience in Latvia","volume":"39","author":"Lejniece","year":"2017","journal-title":"Exp Oncol."},{"issue":"15","key":"2021090315385646100_B23","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1002\/cam4.2545","article-title":"Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States","volume":"8","author":"Abou Dalle","year":"2019","journal-title":"Cancer Med."},{"issue":"12","key":"2021090315385646100_B24","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00277-020-04096-1","article-title":"Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients","volume":"99","author":"Scalzulli","year":"2020","journal-title":"Ann Hematol."},{"issue":"3","key":"2021090315385646100_B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5045\/br.2020.2020130","article-title":"Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study","volume":"55","author":"Gemelli","year":"2020","journal-title":"Blood Res."},{"issue":"7","key":"2021090315385646100_B26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic imatinib in chronic myeloid leukemia: survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"2021090315385646100_B27","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/j.clml.2020.01.009","article-title":"Comparable efficacy and safety of generic imatinib and branded imatinib in patients with newly diagnosed chronic myeloid leukaemia with a consideration of socio-economic characteristics: a retrospective study from a single centre [correction publisher in Clin Lymphoma Myeloma Leuk. 21(1):E84]","volume":"20","author":"Dou","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"12","key":"2021090315385646100_B28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clml.2017.07.255","article-title":"Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec","volume":"17","author":"Eskazan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"1","key":"2021090315385646100_B29","doi-asserted-by":"crossref","first-page":"e2017062","DOI":"10.4084\/mjhid.2017.062","article-title":"Outcome of frontline treatment with \u201cgeneric\u201d imatinib in adult patients with chronic myeloid leukemia in Algerian population: a multicenter study","volume":"9","author":"Entasoltan","year":"2017","journal-title":"Mediterr J Hematol Infect Dis."},{"issue":"1","key":"2021090315385646100_B30","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2019.09.605","article-title":"Evaluation of molecular response to imatinib mesylate treatment in Iranian patients with chronic myeloid leukemia","volume":"20","author":"Nekoohesh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2021090315385646100_B31","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.clml.2015.03.014","article-title":"Factors affecting early molecular response in chronic myeloid leukemia","volume":"15","author":"Chikkodi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"1","key":"2021090315385646100_B32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-020-04289-8","article-title":"Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India","volume":"100","author":"Phukan","year":"2021","journal-title":"Ann Hematol."},{"issue":"12","key":"2021090315385646100_B33","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clml.2017.08.001","article-title":"Generic imatinib therapy among Jordanians: an observational assessment of efficacy and safety in routine clinical practice","volume":"17","author":"Awidi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"9","key":"2021090315385646100_B34","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2019.05.006","article-title":"Generic imatinib in chronic myeloid leukemia treatment: long-term follow-up","volume":"19","author":"\u0106ojba\u0161i\u0107","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"4","key":"2021090315385646100_B35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2017.02.001","article-title":"The efficacy of generic imatinib as first-and second-line therapy: 3-year follow-up of patients with chronic myeloid leukemia","volume":"17","author":"Islamagic","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"35","key":"2021090315385646100_B36","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021090315385646100_B37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood."},{"issue":"7","key":"2021090315385646100_B38","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.3324\/haematol.2018.211235","article-title":"Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study","volume":"104","author":"Klil-Drori","year":"2019","journal-title":"Haematologica."},{"issue":"2","key":"2021090315385646100_B39","doi-asserted-by":"crossref","first-page":"e12423","DOI":"10.1111\/ecc.12423","article-title":"The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients","volume":"26","author":"Uyanik","year":"2017","journal-title":"Eur J Cancer Care (Engl)."},{"issue":"1","key":"2021090315385646100_B40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12937","article-title":"First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate","volume":"167","author":"Eskazan","year":"2014","journal-title":"Br J Haematol."},{"issue":"11","key":"2021090315385646100_B41","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/pds.4893","article-title":"Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia","volume":"28","author":"Cole","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"7","key":"2021090315385646100_B42","doi-asserted-by":"crossref","first-page":"e022328","DOI":"10.1136\/bmjopen-2018-022328","article-title":"Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China","volume":"8","author":"Guan","year":"2018","journal-title":"BMJ Open."},{"issue":"9","key":"2021090315385646100_B43","first-page":"472","article-title":"Anticipated impact of generic imatinib market entry on the costs of tyrosine kinase inhibitors","volume":"8","author":"Bloudek","year":"2015","journal-title":"Am Health Drug Benefits."},{"issue":"7","key":"2021090315385646100_B44","first-page":"333","article-title":"Realized and projected cost-savings from the introduction of generic imatinib through formulary management in patients with chronic myelogenous leukemia","volume":"12","author":"Campbell","year":"2019","journal-title":"Am Health Drug Benefits."},{"issue":"1","key":"2021090315385646100_B45","doi-asserted-by":"crossref","first-page":"e009586","DOI":"10.1136\/bmjopen-2015-009586","article-title":"Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment","volume":"6","author":"Hill","year":"2016","journal-title":"BMJ Open."},{"issue":"7","key":"2021090315385646100_B46","doi-asserted-by":"crossref","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"11","key":"2021090315385646100_B47","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/13696998.2019.1618316","article-title":"Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US","volume":"22","author":"Jabbour","year":"2019","journal-title":"J Med Econ."},{"key":"2021090315385646100_B48"},{"issue":"5","key":"2021090315385646100_B49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1377\/hlthaff.2017.1684","article-title":"Generic Price competition for specialty drugs: too little, too late?","volume":"37","author":"Cole","year":"2018","journal-title":"Health Aff (Millwood)."},{"key":"2021090315385646100_B50"},{"key":"2021090315385646100_B51"},{"issue":"8","key":"2021090315385646100_B52","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","article-title":"ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe [correction published in Ann Oncol. 2020;31(11):P1589]","volume":"27","author":"Cherny","year":"2016","journal-title":"Ann Oncol."},{"key":"2021090315385646100_B53"},{"key":"2021090315385646100_B54"},{"key":"2021090315385646100_B55"},{"key":"2021090315385646100_B56"},{"key":"2021090315385646100_B57","first-page":"917","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","author":"Hochhaus","year":"2017"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3344\/1821171\/advancesadv2021004194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3344\/1821171\/advancesadv2021004194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:56:10Z","timestamp":1630670170000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/17\/3344\/476706\/Current-evidence-on-the-efficacy-and-safety-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":57,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004194","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}